We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients.
- Authors
Mao Lin; Haihua Luo; Shuzhen Liang; Jibing Chen; Aihua Liu; Lizhi Niu; Yong Jiang; Lin, Mao; Luo, Haihua; Liang, Shuzhen; Chen, Jibing; Liu, Aihua; Niu, Lizhi; Jiang, Yong
- Abstract
BACKGROUNDThe anti-programmed cell death 1 (anti-PD-1) antibody pembrolizumab is clinically active against non-small cell lung cancer (NSCLC). In addition to T cells, human natural killer (NK) cells, reported to have the potential to prolong the survival of patients with advanced NSCLC, also express PD-1. This study aimed to investigate the safety and efficacy of pembrolizumab plus allogeneic NK cells in patients with previously treated advanced NSCLC.METHODSIn total, 109 enrolled patients with a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) of 1% or higher were randomly allocated to group A (n = 55 patients given pembrolizumab plus NK cells) or group B (n = 54 patients given pembrolizumab alone). The patients received i.v. pembrolizumab (10 mg/kg) once every 3 weeks and continued treatment until the occurrence of tumor progression or unacceptable toxicity. The patients in group A continuously received 2 cycles of NK cell therapy as 1 course of treatment.RESULTSIn our study, patients in group A had longer survival than did patients in group B (median overall survival [OS]: 15.5 months vs. 13.3 months; median progression-free survival [PFS]: 6.5 months vs. 4.3 months; P < 0.05). In group A patients with a TPS of 50% or higher, the median OS and PFS was significantly longer. Moreover, the patients in group A treated with multiple courses of NK cell infusion had better OS (18.5 months) than did those who received a single course of NK cell infusion (13.5 months).CONCLUSIONPembrolizumab plus NK cell therapy yielded improved survival benefits in patients with previously treated PD-L1+ advanced NSCLC.TRIAL REGISTRATIONClinicalTrials.gov NCT02843204.FUNDINGThis work was supported by grants from the National Natural Science Foundation of China (NSFC) - Guangdong Joint Foundation of China (no. U1601225); the NSFC (no. 81671965); the Guangdong Provincial Key Laboratory Construction Project of China (no. 2017B030314034); and the Key Scientific and Technological Program of Guangzhou City (no. 201607020016).
- Subjects
TREATMENT of lung tumors; LUNG cancer treatment; THERAPEUTIC use of monoclonal antibodies; SAFETY; LUNG cancer; RESEARCH; HOMOGRAFTS; RESEARCH methodology; KILLER cells; MONOCLONAL antibodies; LUNG tumors; EVALUATION research; MEDICAL cooperation; TREATMENT effectiveness; COMPARATIVE studies; RANDOMIZED controlled trials; KAPLAN-Meier estimator; STATISTICAL sampling; ANTIGENS; IMMUNOTHERAPY
- Publication
Journal of Clinical Investigation, 2020, Vol 130, Issue 5, p2560
- ISSN
0021-9738
- Publication type
journal article
- DOI
10.1172/JCI132712